Dispelling the myths of dealmaking trends
This article was originally published in Scrip
The release of Q1 deals data from MedTRACK, showing a 13% fall in pharma/biotech product and technology deal volume compared with last year and a 9% drop on the last quarter of 2010 (see Figure 1), prompted many to question why dealmaking activity is going down when, seemingly, the need for it has never been greater. This natural reaction underlines the importance of understanding, and dispelling, some of the myths and assumptions around deals trending.
Register for our free email digests: